FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Toni Choueiri

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Joaquim Bellmunt; Stéphane Culine; R Fougeray; Jonathan E Rosenberg; Y Salhi; F A Schutz; Hans von der Maase; Toni K Choueiri
Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.
Steven M Bair; Toni K Choueiri; Javid Moslehi
Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.
Guru Sonpavde; Srikala S Sridhar; Walter M Stadler; Cora N Sternberg; Ulka Nitin Vaishampayan; David J Vaughn; Nicholas J Vogelzang; Yu-Ning Wong; Toni K Choueiri; Ronan Fougeray; Matthew D Galsky; Nicholas D James; Awais Khan; Yoo-Joung Ko; Guenter Niegisch; Peter H O'Donnell; Daniel P Petrylak; Gregory R Pond; Angela Q Qu; Jonathan E Rosenberg; Peter Albers; Tomasz M Beer; Joaquim Bellmunt
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Toni Choueiri (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Joaquim Bellmunt; Stéphane Culine; R Fougeray; Jonathan E Rosenberg; Y Salhi; F A Schutz; Hans von der Maase; Toni K Choueiri
Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24(6):1466-72.
2013: Steven M Bair; Toni K Choueiri; Javid Moslehi
Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.
Trends in cardiovascular medicine 2013;23(4):104-13.
2013: Guru Sonpavde; Srikala S Sridhar; Walter M Stadler; Cora N Sternberg; Ulka Nitin Vaishampayan; David J Vaughn; Nicholas J Vogelzang; Yu-Ning Wong; Toni K Choueiri; Ronan Fougeray; Matthew D Galsky; Nicholas D James; Awais Khan; Yoo-Joung Ko; Guenter Niegisch; Peter H O'Donnell; Daniel P Petrylak; Gregory R Pond; Angela Q Qu; Jonathan E Rosenberg; Peter Albers; Tomasz M Beer; Joaquim Bellmunt
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
European urology 2013;63(4):717-23.
2013: Toni K Choueiri; Mark M Pomerantz; Sabina Signoretti
Renal-cell carcinoma: a step closer to a new classification.
The lancet oncology 2013;14(2):105-7.
2013: Daniel Y C Heng; Christian Kollmannsberger; Mary Mackenzie; Meredith M Regan; Sun-Young Rha; Brian I Rini; Min-Han Tan; Ulka Nitin Vaishampayan; Lori Wood; Wanling Xie; Neeraj Agarwal; Georg A Bjarnason; Frede Donskov; Lauren C Harshman; Toni K Choueiri
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.
The lancet oncology 2013;14(2):141-8.
2013: Toni K Choueiri; Peter Eisenberg; Keith T Flaherty; Naomi B Haas; Andrea L Harzstark; Kevin H Laubscher; W Marston Linehan; Theodore F Logan; David F McDermott; Paul S Meltzer; Maria J Merino; Lone H Ottesen; Brian I Rini; Jonathan E Rosenberg; Robert Ross; Laurie Sherman; Sandy Srinivas; Laurel M Adams; Donald P Bottaro; Ronald M Bukowski; Mark N Stein; Ulka Nitin Vaishampayan; Ramaprasad Srinivasan
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(2):181-6.
2013: Arti Parekh; Oliver Sartor; Karen Stein; Charles L Bennett; Ming-Hui Chen; Toni K Choueiri; Anthony V D'Amico; Powell L Graham; Karen E Hoffman; Jim C Hu; Michael W Kattan; Paul L Nguyen
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone.
Urology 2013;81(1):130-4.
2013: Fabio A B Schutz; Sabina Signoretti; Michael B Atkins; Matthew L Freedman; Kathryn P Gray; Michelle S Hirsch; Philip W Kantoff; Megan E Lampron; Gwo-Shu Mary Lee; David F McDermott; Mark M Pomerantz; Jonathan E Rosenberg; Toni K Choueiri
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.
The lancet oncology 2013;14(1):81-7.
2012: Sonia Seng; Guru Sonpavde; Che-Kai Tsao; Menggang Yu; Noah M Hahn; Ziyue Liu; William K Oh; Tracy Proverbs-Singh; Sophia K Chiu; Toni K Choueiri; Matthew D Galsky
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(35):4416-26.
2012: Tracy Proverbs-Singh; Sonia Seng; Guru Sonpavde; Che-Kai Tsao; Menggang Yu; Sophia K Chiu; Toni K Choueiri; Noah M Hahn; Ziyue Liu; William K Oh; Matthew D Galsky
Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.
Journal of the National Cancer Institute 2012;104(23):1837-40.
2012: Hee-Kyung Joh; Eunyoung Cho; Toni K Choueiri
ABO blood group and risk of renal cell cancer.
Cancer epidemiology 2012;36(6):528-32.
2012: Toni K Choueiri; André P Fay; Michelle S Hirsch; Philip W Kantoff; Megan E Lampron; Jesse K McKenney; Emanuele Palescandolo; Michael B Atkins; Victoria Brown; John Cheville; Ming Zhou; Sabina Signoretti
BRAF mutations in metanephric adenoma of the kidney.
European urology 2012;62(5):917-22.
2012: Richard Flavin; Eoin Gaffney; Helen Ingoldsby; Massimo Loda; John J O'Leary; Esther O'Regan; Martina Ring; Miranda Rogers; Ciara Barrett; Toni K Choueiri; Stephen P Finn; Sabina Signoretti; Paul Smyth; Orla Sheils
RET protein expression in papillary renal cell carcinoma.
Urologic oncology 2012;30(6):900-5.
2012: Toni K Choueiri; David McDermott; Maureen P Neary; Sujata P Sarda; Mei Sheng Duh; William K Oh
Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.
Urologic oncology 2012;30(6):848-55.
2012: Robert W Ross; Mary-Ellen Taplin; Clare M Tempany; Wanling Xie; Jerome P Richie; Marc Barry; Rupal S Bhatt; Toni K Choueiri; Phillip G Febbo; Fiona M Fennessy; Matthew D Galsky; Julia Hayes; Philip W Kantoff; William K Oh
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
Cancer 2012;118(19):4777-84.
2012: Samuel J Klempner; Detlef Schuppan; Eric Yee; Toni K Choueiri; Leona A Doyle; Michael B Atkins
Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(27):e264-8.
2012: Lauren C Harshman; Daniel Y C Heng; Jennifer J Knox; Christian Kollmannsberger; Mary MacKenzie; Scott North; Sun-Young Rha; Brian I Rini; Sandy Srinivas; Min-Han Tan; Ulka Nitin Vaishampayan; Lori Wood; Wanling Xie; Neeraj Agarwal; Georg A Bjarnason; Frede Donskov; Toni K Choueiri
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.
The lancet oncology 2012;13(9):927-35.
2012: William D Ulmer; Toni K Choueiri; Christopher Dodgion; Xiangmei Gu; Keith J Kowalczyk; Stuart Lipsitz; Ganesh S Palapattu; Sandip M Prasad; Jim C Hu
Factors associated with the adoption of minimally invasive radical prostatectomy in the United States.
The Journal of urology 2012;188(3):775-80.
2012: Guru Sonpavde; Fabio Schutz; Joaquim Bellmunt; Toni K Choueiri
The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients.
Current oncology reports 2012;14(4):295-306.
2012: Donnette A Dabydeen; Jyothi P Jagannathan; Katherine Krajewski; Ivan Pedrosa; Nikhil Ramaiya; Fabio A B Schutz; Daniel C Cho; Toni K Choueiri
Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome.
European journal of cancer (Oxford, England : 1990) 2012;48(10):1519-24.
2012: Katherine M Krajewski; Francesc Pons; Jonathan E Rosenberg; Yacine Salhi; Fabio A B Schutz; Joaquim Bellmunt; Ronan Fougeray; Toni K Choueiri
Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.
European journal of cancer (Oxford, England : 1990) 2012;48(10):1495-502.
2012: Yolanda D Tseng; Peter F Orio; Andrew A Renshaw; Clair J Beard; Ming-Hui Chen; Toni K Choueiri; Anthony V D'Amico; Jim C Hu; Philip W Kantoff; Marian Loffredo; Neil E Martin; Paul L Nguyen
Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality.
The Journal of urology 2012;187(6):2068-73.
2012: Hua-yin Yu; Toni K Choueiri; Nathanael D Hevelone; Adam S Kibel; Keith J Kowalczyk; Stuart R Lipsitz; Paul L Nguyen; Jim C Hu
Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample.
European urology 2012;61(6):1239-44.
2012: D Y Heng; J J Knox; C Kollmannsberger; M J Mackenzie; S North; B I Rini; M H Tan; Ulka Nitin Vaishampayan; Y Wang; L Wood; G A Bjarnason; F Donskov; Toni K Choueiri
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(6):1549-55.
2012: Robert J Motzer; Thomas Olencki; Roberto Pili; Thomas W Ratliff; Bruce G Redman; Cary N Robertson; Charles J Ryan; Joel Sheinfeld; Jue Wang; Richard B Wilder; Neeraj Agarwal; Clair Beard; Sam Bhayani; Graeme B Bolger; Mark K. Buyyounouski; Michael A Carducci; Sam S Chang; Toni K Choueiri; Shilpa Gupta; Steven L Hancock; Gary R Hudes; Eric Jonasch; Timothy M Kuzel; Clayton Lau; Ellis G Levine; Daniel W Lin; Kim A Margolin; M Dror Michaelson
Testicular cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2012;10(4):502-35.
2012: Paul Nguyen; Sharon A Salenius; Karen E Hoffman; Jim C Hu; Philip W Kantoff; Neil E Martin; Brian J Moran; Clair Beard; Joshua A Beckman; Michelle H Braccioforte; Ming-Hui Chen; Toni K Choueiri; Anthony V D'Amico; Daniel E Dosoretz; Ronald Ennis
Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction.
International journal of radiation oncology, biology, physics 2012;82(4):1411-6.
2012: Fabio A B Schutz; Youjin Je; Christopher J Richards; Toni K Choueiri
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(8):871-7.
2012: Shu-Pin Huang; Chia-Chu Liu; Yeong-Shiau Pu; Ming-Tsang Wu; Tony T Wu; Bo-Ying Bao; Toni K Choueiri; William B Goggins; Chun-Hsiung Huang; Chun-Nung Huang; Chao-Yuan Huang; Chia-Cheng Yu; Wen-Jeng Wu
Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy.
The aging male : the official journal of the International Society for the Study of the Aging Male 2012;15(1):34-41.
2012: Toni K Choueiri; Mario A Eisenberger; Noah M Hahn; Thomas E Hutson; Susanna Jacobus; Glenn J Bubley; Geoffrey C Buckle; William Y Kim; Stephanie C Morrissey; Amir Mortazavi; Daniel P Petrylak; David I Quinn; Jonathan E Rosenberg; Robert W Ross; Christopher W Ryan; Guru Sonpavde; Mary-Ellen Taplin; Ulka Nitin Vaishampayan; Evan Y Yu; Philip W Kantoff
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(5):507-12.
2012: Wei Liu; Toni K Choueiri; Eunyoung Cho
Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts.
Cancer 2012;118(3):797-803.
2011: Paul L Nguyen; Arti Parekh; Fabio A B Schutz; Joshua A Beckman; Karen E Hoffman; Jim C Hu; Youjin Je; Toni K Choueiri
Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
JAMA : the journal of the American Medical Association 2011;306(21):2359-66.
2011: Nizar M Tannir; Yu-Ning Wong; Leonard J Appleman; Dawn M Carlson; Jihong Chen; Daniel Cho; Toni K Choueiri; Andrew Coates; Marc S Ernstoff; Neeraj Gupta; Christian K Kollmannsberger; David J Perry; Edwin M Posadas; Rajendra Pradhan; Jiang Qian; Justin L Ricker; Frank Scappaticci; M Dror Michaelson
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.
European journal of cancer (Oxford, England : 1990) 2011;47(18):2706-14.
2011: Stephen B Williams; Toni K Choueiri; Xiangmei Gu; Stuart R Lipsitz; Paul L Nguyen; Jim C Hu
Utilization and expense of adjuvant cancer therapies following radical prostatectomy.
Cancer 2011;117(21):4846-54.
2011: Fabio A B Schutz; Youjin Je; Toni K Choueiri
Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.
Critical reviews in oncology/hematology 2011;80(2):291-300.
2011: Aymen A Elfiky; Barry Fortner; Sujata S Jayawant; David F McDermott; William K Oh; Jonathan E Rosenberg; Mei Sheng Duh; Lucia Antràs; Michael B Atkins; Kristina Chen; Daniel C Cho; Toni K Choueiri
Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
Urologic oncology 2011;29(6):756-63.
2011: Debra Josephs; Chris Karapetis; James M Larkin; David F McDermott; Lisa M Pickering; Thomas Powles; Mieke Van Hemelrijck; Charles L Cowey; Martin E Gore; Peter G Harper; Thomas E Hutson; Toni K Choueiri; Paramit Chowdhury; Simon Chowdhury
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
BJU international 2011;108(8):1279-83.
2011: Eunyoung Cho; Michael B Atkins; Gary Curhan; Susan E Hankinson; Philip Kantoff; Meir Stampfer; Toni K Choueiri
Prospective evaluation of analgesic use and risk of renal cell cancer.
Archives of internal medicine 2011;171(16):1487-93.
2011: Robert J Motzer; Thomas Olencki; Roberto Pili; Thomas W Ratliff; Bruce G Redman; Cary N Robertson; Charles J Ryan; Joel Sheinfeld; Philippe E Spiess; Jue Wang; Richard B Wilder; Neeraj Agarwal; Clair Beard; Sam Bhayani; Graeme B Bolger; Michael A Carducci; Sam S Chang; Toni K Choueiri; Steven L Hancock; Gary R Hudes; Eric Jonasch; David Josephson; Timothy M Kuzel; Ellis G Levine; Daniel W Lin; Kim A Margolin; M Dror Michaelson
Kidney cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9(9):960-77.
2011: Christopher J Richards; Fabio A B Schutz; Susan M Dallabrida; Daniel Y C Heng; Youjin Je; Javid J Moslehi; Toni K Choueiri
Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(25):3450-6.
2011: Stephen B Williams; Timothy G Wilson; Toni K Choueiri; David Y Josephson; Clayton S Lau; Aaron H Lay; Sumanta K Pal
New therapies for castrate-resistant prostate cancer.
Expert opinion on pharmacotherapy 2011;12(13):2069-74.
2011: Judith Manola; Madhu Mazumdar; Jennifer Bacik McCormack; Robert Motzer; Sylvie Négrier; Patrick Royston; Michael Atkins; Ronald Bukowski; Toni K Choueiri; Janice Dutcher; Tim Eisen; Paul Elson; Bernard Escudier; Daniel Y C Heng
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(16):5443-50.
2011: Toni K Choueiri
VEGF inhibitors in metastatic renal cell carcinoma: current therapies and future perspective.
Current clinical pharmacology 2011;6(3):164-8.
2011: Simon Chowdhury; Marc R Matrana; Bradley Atkinson; Toni K Choueiri; Christopher Tsang; Nizar M Tannir
Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.
Hematology/oncology clinics of North America 2011;25(4):853-69.
2011: Toni K Choueiri
Renal cell carcinoma.
Hematology/oncology clinics of North America 2011;25(4):xiii-xiv.
2011: Guru Sonpavde; Neeraj Agarwal; Toni K Choueiri; Philip W Kantoff
Recent advances in immunotherapy for the treatment of prostate cancer.
Expert opinion on biological therapy 2011;11(8):997-1009.
2011: Shu-Pin Huang; Yeong-Shiau Pu; Ming-Tsang Wu; Chia-Cheng Yu; Bo-Ying Bao; Toni K Choueiri; William B Goggins; Chao-Yuan Huang; Chun-Hsiung Huang
Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy.
The Prostate 2011;71(11):1189-97.
2011: Toni K Choueiri; Nathanael D Hevelone; Stuart R Lipsitz; Paul L Nguyen; Fabio A B Schutz; Stuart G Silverman; Stephen B Williams; Jim C Hu
Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis.
Urology 2011;78(1):93-8.
2011: Fabio A B Schutz; Jonathan E Rosenberg; Joaquim Bellmunt; Toni K Choueiri
Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid.
Expert opinion on drug safety 2011;10(4):645-53.
2011: Daniel Y C Heng; Jennifer Knox; Christian Kollmannsberger; Brian I Rini; Min-Han Tan; Ulka Nitin Vaishampayan; Lori Wood; Wanling Xie; Georg A Bjarnason; Frede Donskov; Toni K Choueiri
Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.
Cancer 2011;117(12):2637-42.
2011: F A B Schutz; Y Je; G R Azzi; P L Nguyen; Toni K Choueiri
Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(6):1404-12.
2011: Kavitha Parithivel; Nikhil Ramaiya; Jyothi Priya Jagannathan; Kevin O'Regan; Katherine Krajewski; David Fisher; Toni K Choueiri; Eric Jacobsen
Everolimus- and temsirolimus-associated enteritis: report of three cases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(14):e404-6.
2011: Fabio A B Schutz; Denis L F Jardim; Youjin Je; Toni K Choueiri
Haematologic toxicities associated with the addition of bevacizumab in cancer patients.
European journal of cancer (Oxford, England : 1990) 2011;47(8):1161-74.
2011: Katherine M Krajewski; Mengye Guo; Annick D Van den Abbeele; Jeffrey Yap; Nikhil Ramaiya; Jyothi Jagannathan; Daniel Y C Heng; Michael B Atkins; David F McDermott; Fabio A B Schutz; Ivan Pedrosa; Toni K Choueiri
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
European urology 2011;59(5):856-62.
2011: Paul Nguyen; Xiangmei Gu; Stuart R Lipsitz; Toni K Choueiri; Wesley W Choi; Yin Lei; Karen E Hoffman; Jim C Hu
Cost implications of the rapid adoption of newer technologies for treating prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(12):1517-24.
2011: Paul Nguyen; Ming H Chen; Toni K Choueiri; Karen E Hoffman; Jim C Hu; Neil E Martin; Clair J Beard; Daniel E Dosoretz; Brian J Moran; Michael J Katin; Michelle H Braccioforte; Rudi Ross; Sharon A Salenius; Philip W Kantoff; Anthony V D'Amico
Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size.
International journal of radiation oncology, biology, physics 2011;79(5):1318-22.
2011: Fabio A B Schutz; Toni K Choueiri; Cora N Sternberg
Pazopanib: Clinical development of a potent anti-angiogenic drug.
Critical reviews in oncology/hematology 2011;77(3):163-71.
2011: Toni K Choueiri; Erica L Mayer; Youjin Je; Jonathan E Rosenberg; Paul L Nguyen; Georges R Azzi; Joaquim Bellmunt; Harold J Burstein; Fabio A B Schutz
Congestive heart failure risk in patients with breast cancer treated with bevacizumab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(6):632-8.
2011: Gary R Hudes; Michael A Carducci; Toni K Choueiri; Peg Esper; Eric Jonasch; Rashmi Kumar; Kim A Margolin; M Dror Michaelson; Robert J Motzer; Roberto Pili; Susan Roethke; Sandy Srinivas
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9 Suppl 1():S1-29.
2011: Joaquim Bellmunt; Toni K Choueiri; F A B Schutz; J E Rosenberg
Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(2):245-7.
2011: Jose A Karam; Brian I Rini; Leticia Varella; Jorge A Garcia; Robert Dreicer; Toni K Choueiri; Eric Jonasch; Surena F Matin; Steven C Campbell; Christopher G Wood; Nizar M Tannir
Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.
The Journal of urology 2011;185(2):439-44.
2011: Jim C Hu; Sandip M Prasad; Xiangmei Gu; Stephen B Williams; Stuart R Lipsitz; Paul L Nguyen; Toni K Choueiri; Wesley W Choi; Anthony V D'Amico
Determinants of performing radical prostatectomy pelvic lymph node dissection and the number of lymph nodes removed in elderly men.
Urology 2011;77(2):402-6.
2011: PA Tang; Daniel Y C Heng; Toni K Choueiri
Impact of body composition on clinical outcomes in metastatic renal cell cancer.
The oncologist 2011;16(11):1484-6.
2011: Toni K Choueiri; Wanling Xie; Christian Kollmannsberger; Scott North; Jennifer J Knox; J Geoffrey Lampard; David F McDermott; Brian I Rini; Daniel Y C Heng
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
The Journal of urology 2011;185(1):60-6.
2011: Karen E Hoffman; Paul L Nguyen; Ming-Hui Chen; Ronald C Chen; Toni K Choueiri; Jim C Hu; Deborah A Kuban; Anthony V D'Amico
Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials.
The Journal of urology 2011;185(1):116-20.
2010: Ivan N Zama; Thomas E Hutson; Paul Elson; James M Cleary; Toni K Choueiri; Daniel Y C Heng; Nikhil Ramaiya; M Dror Michaelson; Jorge A Garcia; Jennifer J Knox; Bernard Escudier; Brian I Rini
Sunitinib rechallenge in metastatic renal cell carcinoma patients.
Cancer 2010;116(23):5400-6.
2010: Emily S Robinson; Eliyahu V Khankin; Toni K Choueiri; Mallika S Dhawan; Miranda J Rogers; S Ananth Karumanchi; Benjamin D Humphreys
Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.
Hypertension 2010;56(6):1131-6.
2010: Toni K Choueiri; Zita Dubauskas Lim; Michelle S Hirsch; Pheroze Tamboli; Eric Jonasch; David F McDermott; Paola Dal Cin; Paul Corn; Ulka Nitin Vaishampayan; Daniel Y C Heng; Nizar M Tannir
Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.
Cancer 2010;116(22):5219-25.
2010: Leah Katz; Toni K Choueiri; Joaquim Bellmunt
¹¹C-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy.
BJU international 2010;106(9):1249-50.
2010: Deborah A Ahove; Karen E Hoffman; Jim C Hu; Toni K Choueiri; Anthony V D'Amico; Paul L Nguyen
Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy.
Urology 2010;76(5):1201-5.
2010: Julia H Hayes; Ming-Hui Chen; Brian J Moran; Michelle H Braccioforte; Daniel E Dosoretz; Sharon Salenius; Michael J Katin; Rudi Ross; Toni K Choueiri; Anthony V D'Amico
Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke.
BJU international 2010;106(7):979-85.
2010: Paul J Kelly; Stephanie E Weiss; David J Sher; Antonio R Perez-Atayde; Paola Dal Cin; Toni K Choueiri
Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(25):e433-5.
2010: Toni K Choueiri; Meredith M Regan; Jonathan E Rosenberg; William K Oh; Jessica Clement; Angela M Amato; David McDermott; Daniel C Cho; Michael B Atkins; Sabina Signoretti
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
BJU international 2010;106(6):772-8.
2010: Michael M Vickers; Toni K Choueiri; Miranda Rogers; Andrew Percy; Daygen Finch; Ivan Zama; Tina Cheng; Scott North; Jennifer J Knox; Christian Kollmannsberger; David F McDermott; Brian I Rini; Daniel Y Heng
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy.
Urology 2010;76(2):430-4.
2010: Kevin D Courtney; Toni K Choueiri
Updates on novel therapies for metastatic renal cell carcinoma.
Therapeutic advances in medical oncology 2010;2(3):209-19.
2010: Toni K Choueiri; Fabio A B Schutz; Youjin Je; Jonathan E Rosenberg; Joaquim Bellmunt
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(13):2280-5.
2010: Paul Swinburn; Andrew Lloyd; Paul Nathan; Toni K Choueiri; David Cella; Maureen P Neary
Elicitation of health state utilities in metastatic renal cell carcinoma.
Current medical research and opinion 2010;26(5):1091-6.
2010: Toni K Choueiri; Mei Sheng Duh; Jessica Clement; Ashley J Brick; Miranda J Rogers; Christabel Kwabi; Karishma Shah; Andrew G Percy; Lucia Antràs; Sujata S Jayawant; Kristina Chen; Si-Tien Wang; Andi Luka; Maureen P Neary; David McDermott; William K Oh
Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.
BJU international 2010;105(9):1247-54.
2010: Toni K Choueiri; Ming-Hui Chen; Anthony V D'Amico; Leon Sun; Paul L Nguyen; Julia H Hayes; Cary N Robertson; Philip J Walther; Thomas J Polascik; David M Albala; Judd W Moul
Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.
Cancer 2010;116(8):1887-92.
2010: Joaquim Bellmunt; Toni K Choueiri; Ronan Fougeray; Fabio A B Schutz; Yacine Salhi; Eric Winquist; Stéphane Culine; Hans von der Maase; David J Vaughn; Jonathan E Rosenberg
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(11):1850-5.
2010: Toni K Choueiri
Prognostic factors in patients treated with VEGF-targeted therapies.
Clinical advances in hematology & oncology : H&O 2010;8(2):92-3.
2010: Paul L Nguyen; Ming-Hui Chen; Clair J Beard; W Warren Suh; Toni K Choueiri; Jason A Efstathiou; Karen E Hoffman; Marian Loffredo; Philip W Kantoff; Anthony V D'Amico
Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence.
Cancer 2010;116(3):610-5.
2009: Toni K Choueiri; Michael B Atkins
Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?
Nature reviews. Clinical oncology 2009;6(12):679-80.
2009: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(34):5794-9.
2009: Toni K Choueiri; Juan-Miguel Mosquera; Michelle S Hirsch
A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib.
Clinical genitourinary cancer 2009;7(3):E93-4.
2009: Youjin Je; Fabio A B Schutz; Toni K Choueiri
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
The lancet oncology 2009;10(10):967-74.
2009: Joaquim Bellmunt; Jonathan E Rosenberg; Toni K Choueiri
Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer.
European urology 2009;56(4):606-8.
2009: Fredrik Wiklund; Steinar Tretli; Toni K Choueiri; Sabina Signoretti; Katja Fall; Hans-Olov Adami
Risk of bilateral renal cell cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(23):3737-41.
2009: Toni K Choueiri; Joaquim Bellmunt
Sunitinib in renal-cell carcinoma: expanded indications.
The lancet oncology 2009;10(8):740.
2009: Mei Sheng Duh; Ellison Dial; Toni K Choueiri; Andree-Anne Fournier; Lucia Antras; Douglas Rodermund; Maureen P Neary; William K Oh
Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.
Current medical research and opinion 2009;25(8):2081-90.
2009: Daniel Y C Heng; Toni K Choueiri
Non-clear cell renal cancer: features and medical management.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(6):659-65.
2009: Robert J Motzer; Neeraj Agarwal; Clair Beard; Graeme B Bolger; Barry Boston; Michael A Carducci; Toni K Choueiri; Robert A Figlin; Mayer Fishman; Steven L Hancock; Gary R Hudes; Eric Jonasch; Anne Kessinger; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Kim A Margolin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Bruce G Redman; Cary N Robertson; Lawrence H Schwartz; Joel Sheinfeld; Jue Wang
NCCN clinical practice guidelines in oncology: kidney cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(6):618-30.
2009: Robert J Motzer; Neeraj Agarwal; Clair Beard; Graeme B Bolger; Barry Boston; Michael A Carducci; Toni K Choueiri; Robert A Figlin; Mayer Fishman; Steven L Hancock; Gary R Hudes; Eric Jonasch; Anne Kessinger; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Kim A Margolin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Bruce G Redman; Cary N Robertson; Lawrence H Schwartz; Joel Sheinfeld; Jue Wang
NCCN clinical practice guidelines in oncology: testicular cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(6):672-93.
2009: Jacques Medioni; Toni K Choueiri; Franck Zinzindohoué; Daniel Cho; Laure Fournier; Stéphane Oudard
Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis.
The Journal of urology 2009;181(6):2470-5; discussion 2475.
2009: Michael B Atkins; Toni K Choueiri; Daniel Cho; Meredith Regan; Sabina Signoretti
Treatment selection for patients with metastatic renal cell carcinoma.
Cancer 2009;115(10 Suppl):2327-33.
2009: Kevin D Courtney; Toni K Choueiri
Optimizing recent advances in metastatic renal cell carcinoma.
Current oncology reports 2009;11(3):218-26.
2009: Simon Chowdhury; Toni K Choueiri
Recent advances in the systemic treatment of metastatic papillary renal cancer.
Expert review of anticancer therapy 2009;9(3):373-9.
2009: Toni K Choueiri; Wanling Xie; Anthony V D'Amico; Robert W Ross; Jim C Hu; Mark Pomerantz; Meredith M Regan; Mary-Ellen Taplin; Philip W Kantoff; Oliver Sartor; William K Oh
Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
Cancer 2009;115(5):981-7.
2008: Simon Chowdhury; Peter G Harper; Toni K Choueiri
The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy.
Nature clinical practice. Oncology 2008;5(12):698-9.
2008: Jim C Hu; Nathanael D Hevelone; Marcos D Ferreira; Stuart R Lipsitz; Toni K Choueiri; Martin G Sanda; Craig C Earle
Patterns of care for radical prostatectomy in the United States from 2003 to 2005.
The Journal of urology 2008;180(5):1969-74.
2008: Brian I Rini; Toni K Choueiri; Paul Elson; Mohamad K Khasawneh; Claudiu Cotta; Jaya Unnithan; Laura Wood; Tarek Mekhail; Jorge Garcia; Robert Dreicer; Ronald M Bukowski
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
Cancer 2008;113(6):1309-14.
2008: Toni K Choueiri; Susan A J Vaziri; Erich Jaeger; Paul Elson; Laura Wood; Ish Prasad Bhalla; Eric J Small; Vivian Weinberg; Nancy Sein; Jeff Simko; Ali-Reza Golshayan; Linda Sercia; Ming Zhou; Frederic M Waldman; Brian I Rini; Ronald M Bukowski; Ram Ganapathi
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
The Journal of urology 2008;180(3):860-5; discussion 865-6.
2008: Toni K Choueiri; Derek Raghavan
Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties.
Nature clinical practice. Oncology 2008;5(8):444-54.
2008: Toni K Choueiri
Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.
Current opinion in investigational drugs (London, England : 2000) 2008;9(6):658-71.
2008: Toni K Choueiri
Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenic agents.
Clinical genitourinary cancer 2008;6(1):15-20.
2008: Toni K Choueiri; Robert Dreicer; Alan Paciorek; Peter R Carroll; Badrinath R Konety
A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.
The Journal of urology 2008;179(3):906-10; discussion 910.
2008: Toni K Choueiri; Rachid C Baz; Carolyn M McFadden; Mohamad Khasawneh; Mary Ann Karam; Megan Kelly; Mohamad A Hussein
An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications.
BJU international 2008;101(6):712-5.
2008: Ali-Reza Golshayan; Ashley J Brick; Toni K Choueiri
Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
Future oncology (London, England) 2008;4(1):85-92.
2008: Toni K Choueiri; Anne Plantade; Paul Elson; Sylvie Negrier; Alain Ravaud; Stéphane Oudard; Ming Zhou; Brian I Rini; Ronald M Bukowski; Bernard Escudier
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(1):127-31.
2007: Bernard Escudier; Toni K Choueiri; Stéphane Oudard; Cezary Szczylik; Sylvie Négrier; Alain Ravaud; Christine Chevreau; Peter Venner; Patrick Champagne; Daniel Croteau; Eric Dupont; Claude Hariton; Ronald M Bukowski
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
The Journal of urology 2007;178(5):1901-5.
2007: Ila Tamaskar; Toni K Choueiri; Linda Sercia; Brian I Rini; Ronald Bukowski; Ming Zhou
Differential expression of caveolin-1 in renal neoplasms.
Cancer 2007;110(4):776-82.
2007: Toni K Choueiri; Jorge A Garcia; Paul Elson; Mohamad Khasawneh; Saif Usman; Ali-Reza Golshayan; Rachid Baz; Laura Wood; Brian I Rini; Ronald M Bukowski
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Cancer 2007;110(3):543-50.
2007: Toni K Choueiri; Andrew J Stephenson; Timothy Gilligan; Eric A Klein
Management of clinical stage I nonseminomatous germ cell testicular cancer.
The Urologic clinics of North America 2007;34(2):137-48; abstract viii.
2007: Sarah M Short; Brian J Yoder; Shannon Tarr; Nichole L Prescott; Simas Laniauskas; Kara A Coleman; Erinn Downs-Kelly; James Pettay; Toni K Choueiri; Joseph P Crowe; Raymond R Tubbs; Thomas G Budd; David G Hicks
The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study.
The breast journal 2007;13(2):130-9.
2007: Toni K Choueiri; Brian I Rini; Jorge A Garcia; Rachid Baz; Rony M Abou-Jawde; Snehal G Thakkar; Paul Elson; Tarek Mekhail; M Zhou; Ronald M Bukowski
Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(2):249-55.
2007: Rachid Baz; Esteban Walker; Toni K Choueiri; Rony M Abou-Jawde; C Brand; B McGowan; E Yiannaki; Steven Andresen; Mohamad A Hussein
Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma.
Acta haematologica 2007;117(3):162-7.
2006: Toni K Choueiri; Robert Dreicer; Brian I Rini; Paul Elson; Jorge A Garcia; Snehal G Thakkar; Rachid Baz; Tarek Mekhail; Holly A Jinks; Ronald M Bukowski
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.
Cancer 2006;107(11):2609-16.
2006: Rachid Baz; Esteban Walker; Mary Ann Karam; Toni K Choueiri; Rony Abou Jawde; K Bruening; Janice Reed; Beth Faiman; Y Ellis; C Brand; Gordan Srkalovic; Steven Andresen; R Knight; Jerome B Zeldis; Mohamad A Hussein
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(12):1766-71.
2006: David G Hicks; Brian J Yoder; Sarah Short; Shannon Tarr; Nichole L Prescott; Joseph P Crowe; Andrea E Dawson; G Thomas Budd; Steven Sizemore; Muzaffer Cicek; Toni K Choueiri; Raymond R Tubbs; Daniel P Gaile; Norma J Nowak; Mary Ann Accavitti-Loper; Andra R Frost; Danny R Welch; Graham Casey
Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(22):6702-8.
2006: Toni K Choueiri; Ronald M Bukowski; Brian I Rini
The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
Seminars in oncology 2006;33(5):596-606.
2006: Rony M Abou-Jawde; Rachid Baz; Esteban Walker; Toni K Choueiri; Mary Ann Karam; Janice Reed; Beth Faiman; Mohamad Hussein
The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma.
Haematologica 2006;91(10):1410-3.
2006: David G Hicks; Sarah M Short; Nichole L Prescott; Shannon Tarr; Kara A Coleman; Brian J Yoder; Joseph P Crowe; Toni K Choueiri; Andrea E Dawson; G Thomas Budd; Raymond R Tubbs; Graham Casey; Robert J Weil
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.
The American journal of surgical pathology 2006;30(9):1097-104.
2006: Toni K Choueiri; Tarek Mekhail; Thomas E Hutson; Ram Ganapathi; G E Kelly; Ronald M Bukowski
Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(5):860-5.
2006: Snehal G Thakkar; Toni K Choueiri; Jorge A Garcia
Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.
Current oncology reports 2006;8(2):108-13.
2006: Toni K Choueiri; Robert Wesolowski; Tarek Mekhail
Phenoxodiol: isoflavone analog with antineoplastic activity.
Current oncology reports 2006;8(2):104-7.
2005: Jennifer K Long; Toni K Choueiri; Gerri S Hall; Robin K Avery; Mikkael A Sekeres
Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia.
Mayo Clinic proceedings. Mayo Clinic 2005;80(9):1215-6.
2004: Toni K Choueiri; Carlos Alemany; Rony M Abou-Jawde; G Thomas Budd
Role of aromatase inhibitors in the treatment of breast cancer.
Clinical therapeutics 2004;26(8):1199-214.
2003: Toni K Choueiri; Thomas E Hutson; Ronald M Bukowski
Evolving role of pegylated interferons in metastatic renal cell carcinoma.
Expert review of anticancer therapy 2003;3(6):823-9.
2003: Steven R Deitcher; Toni K Choueiri; Gordan Srkalovic; Mohamad A Hussein
Acquired activated protein C resistance in myeloma patients with venous thromboembolic events.
British journal of haematology 2003;123(5):959.
2003: Rony M Abou-Jawde; Toni K Choueiri; Carlos Alemany; Tarek Mekhail
An overview of targeted treatments in cancer.
Clinical therapeutics 2003;25(8):2121-37.
2002: Toni K Choueiri; Alan E Lichtin
Hereditary hemorrhagic telangiectasia, idiopathic thrombocytopenic purpura, and chronic lymphocytic leukemia treated with rituximab.
The American journal of medicine 2002;113(8):700-1.
2002: Toni K Choueiri; Steven R Deitcher
Why shouldn't we use warfarin alone to treat acute venous thrombosis?
Cleveland Clinic journal of medicine 2002;69(7):546-8.